Even in fields in which women are well represented, they are up to 40% more likely than men to leave research within 20 years ...

Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year,” said ...